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When a stem cell divides, it can produce a copy of itself as well as differentiated
cell progeny. Stem cells allow the generation of embryonic tissues (embryonic
stem cells) and the maintenance of adult tissue (adult stem cells). Stem cells play a
key role in embryonic development. A complex organism derives from a single
cell, the fertilized egg. During embryogenesis, cells are initially proliferative and
pluripotent; they only gradually become restricted to different cell fates. The first
evidence of pluripotent stem cells’ existence in the embryo comes from the 1960-
1970s, when it was seen that early mouse embryos transplanted to ectopic sites
produced teratocarcinomas, tumors that contain a variety of differentiated cell
types as well as embryonal carcinoma (EC) cells (undifferentiated cells).
1 A tumor
containing both EC cells and differentiated cells can be generated from one EC
cell.
2 In the 1970s, it was shown that when EC cells were injected back into early
embryos, they could reveal their pluripotency and participate in the formation of
chimeras.
3,4 But it was not until 1981 that Martin
5 and Evans and Kaufman
6
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MicroRNAs (miRNAs) are small non-coding RNAs that regulate messenger
RNAs at the post-transcriptional level. They play an important role in the control
of cell physiological functions, and their alterations have been related to cancer,
where they can function as oncogenes or tumor suppressor genes. Recently, they
have emerged as key regulators of “stemness”, collaborating in the maintenance of
pluripotency, control of self-renewal, and differen-tiation of stem cells. The
miRNA pathway has been shown to be crucial in embryonic development and in
embryonic stem (ES) cells, as shown by Dicer knockout analysis. Specific patterns
of miRNAs have been reported to be expressed only in ES cells and in early
phases of embryonic development. Moreover, many cancers present small
populations of cells with stem cell characteristics, called cancer stem cells (CSCs).
CSCs are responsible for relapse and treatment failure in many cancer patients,
and the comparative analysis of expression patterns between ES cells and tumors
can lead to the identification of a miRNA signature to define CSCs. Most of the
key miRNAs identified to date in ES cells have been shown to play a role in tumor
diagnosis or prognosis, and may well prove to be essential in cancer therapy in the
foreseeable future. 
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INTRODUCTIONdiscovered embryonic stem (ES) cells, permanent pluri-
potent cell lines which could be derived directly from an
embryo at blastocyst stage. 
ES cells may participate in normal embryonic develop-
ment when they are injected into the blastocyst. In contrast,
ES cells develop into tumors if injected in ectopic sites in
adult mice. Moreover, the role of microenvironment in the
growth control of embryonic stem cells has also been exa-
mined. When ES cells were injected in pregnant mouse
uteri, no tumor formation was observed; in contrast, the ES
cells injected into pseudopregnant uteri often developed
into tumors, and those injected into non-pregnant uteri
always developed into teratocarcinomas. These results
showed that the pregnant-uterine microenvironment may
participate in the control of ES cell growth.
7 Now we know
that stem cells are controlled by extrinsic signals from their
regulatory niche and also by intrinsic factors like the hyper-
dynamic plasticity of chromatin proteins.
8 In summary, ES
cells can readily be shown to differentiate into essentially
all cell phenotypes, whereas most isolates of adult stem cells
have more limited potential for differentiation. Both retain
the capacity to divide indefinitely, and this division must be
finely regulated because few divisions can alter tissue
homeostasis and many divisions can drive to cancer initia-
tion. Many cancers present small populations of cells with
stem cell characteristics, called cancer stem cells (CSCs).
Recently, novel elements, microRNAs (miRNAs), have
emerged as crucial regulators for proper stem cell mainte-
nance and function (Fig. 1). 
miRNA characteristics
miRNAs are small non-coding RNAs (22-24 nucleotides
in length) that negatively regulate messenger RNA transla-
tion to protein by binding to 3’UTRs of target messenger
RNA.
9 These molecules were described for the first time in
1993 by Victor Ambros and colleagues in Caenorhabditis
elegans, and to date, more than 700 miRNAs have been
identified in humans. They are encoded in the entire ge-
nome, including the exonic, intronic, and intergenic regions,
but 90% are found in intronic regions.
10 They are transcrib-
ed from these regions through RNA polymerase II action -
first as large molecules, called pri-miRNAs, that can exceed
1 Kb and that could be a polycistronic transcript containing
more than one miRNA. In the same nucleus they are pro-
cessed by RNase complexes (Drosha and DGCR8) into -70
nucleotide fragments with stem-loop structures called pre-
miRNAs. The pre-miRNA is exported to the cytoplasm by
Exportin-5 and RAN is the official full name action. There
it is further cleaved by Dicer action to generate a duplex
molecule of -25 nucelotides in length. These duplex
molecules bind a protein complex called the RNA induced
silencing complex (RISC), where one of the two chains is
selected, known as mature miRNA, to guide this complex
to the target mRNA. In general, when a miRNA and a
mRNA exhibit total complementarities, RISC is capable of
degrading target mRNA, whereas if base pairing com-
plementarity is incomplete, translational silencing of the
target occurs. Through these mechanisms, miRNAs
decrease translation of human genes (Fig. 2).
9,10
Since their discovery, miRNAs have been shown as
powerful key regulator elements, since a single miRNA
can silence several hundreds of genes and one gene can be
targeted by several miRNAs, producing different grades of
repression.
9 miRNAs target a large number of genes in
relation to a great variety of biological processes, including
regulation of proliferation and apoptosis and stem cell self-
renewal and differentiation. Moreover, miRNA expression
is regulated in a tissue- and developmental stage-specific
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Fig. 1.Timeline showing the main discoveries in stem cell biology and miRNA research. miRNA, microRNA.manner.
11-15
miRNA deregulation is thus related to an increasing
number of diseases, including cancer. All the mechanisms
that can alter the normal expression of a gene can affect the
expression of a miRNA, including chromosomal transloca-
tions, amplifications, and deletions or mutations.
16 High-
throughput analyses have shown that miRNA expression is
commonly deregulated in several types of cancer.
17 
miRNAs in stem cell regulation
ES cell regulation by miRNAs
Human ES cells are cell lines established from the explanted
inner cell mass of human blastocysts. Experiments with
Dicer and DGCR8 knockouts have provided evidence that
miRNAs play a crucial role in development in general and
specifically in ES cells. Dicer deletion is lethal in the early
stages of development in Drosophila
18 and mice.
19 Dicer
conditional knockouts showed defects in proliferation,
miRNA maturation, and differentiation,
20,21 and DGCR8
conditional knockout showed defects in proliferation and
cell cycle progression,
22 demonstrating that the miRNA
pathway is closely related with the regulation of ES cells.
Houbaviy, et al.
23 were the first to analyze ES cell-specific
miRNAs. They identified a signature of overexpressed
miRNAs in mouse ES cells that were repressed as they
differentiated into embryoid bodies and were absent in the
adult organ tissues. From the set of miRNAs identified, the
authors distinguished three groups of miRNAs: miRNAs
with ES cell-specific functions (the miR-290-295 cluster
and miR-296); miRNAs also found in adult tissues, which
could thus regulate general cell physiology (miR-15a,
miR-16, miR-19b, miR-92, miR-93, miR-96, miR-130 and
miR-130b); and miRNAs whose expression increases
upon differentiation (miR-21 and miR-22).
One year later, Suh, et al.
24 reported the first miRNA sig-
nature in human ES (hES) cells. As in the previous work,
the miRNAs identified are related to each other in clusters
(polycistronic primary transcripts). They identified 36
miRNAs and grouped them into four categories: ES cell-
specific miRNAs (miR-200c, 368, 154*, 371, 372, 373*,
373); miRNAs found in both ES cells and their malignant
counterpart the EC cells (miR-302a, 302a*, 302b, 302b*,
302c, 302c*, 302d and 367); miRNAs that are rare in ES
cells but abundant in Hela and STO cell lines (let-7a, miR-
301, 374, 21, 29b, 29); and miRNAs expressed in the
majority of the cell lines tested (miR-16, 17-5p, 19b, 26a,
92, 103, 130a and 222). 
ES cell identity can be formed by the transcription factors
Nanog, OCT4, and Sox2.
25-31 These genes can be regulated
by miR-134, miR-296, and miR-470.
32 Moreover, Marson,
et al.
33 report that these genes regulate the expression of
Alfons Navarro and Mariano Monzó
Yonsei Med J   http://www.eymj.org    Volume 51   Number 5   September 2010 624
Fig. 2.miRNA biogenesis pathway.miRNAs related to the pluripotency state by binding to the
promoter region. The miR-302-367 cluster is one of the
miRNAs regulated by these transcription factors and its
expression is restricted to the ES cell compartment. This
cluster regulates the cell cycle by promoting self-renewal
and pluripotency.
34
Analyses of the role of miRNAs in the differentiation of
hES cell lines have identified two groups of miRNAs:
those that are expressed in the undifferentiated state and
are markers of pluripotency (miR-200c, 371, 372, 302a,
320d , 373, 302c, 21, 222, 296, 494, 367), and miRNAs that
act to regulate the differentiation of cells into one of the
different embryonic lineages (miR-17, 92 and 93, which
are overexpressed in differentiated cells, and miR-154,
29a, 143, 29c, and let-7a, which are underexpressed in dif-
ferentiated cells).
35 In an analysis of miRNAs that change
during hES cell differentiation into embryoid bodies, a set
of 30 miRNAs was identified, some of which had previou-
sly been identified as let-7a.
36 The majority of the miRNAs
that characterize hES cells are expressed from chromo-
somes 19 and X.
36
Other investigators examined the target related to hES
cell-specific miRNAs, and identified TRPS1 and KLF13
transcription factors and MBNL2 a RNA binding protein
as targets of miR-302d and miR-372.
37 The same authors
identified in these hES cell lines a set of miRNAs upregul-
ated (miR-372, 302d, 367, 200c, 199a, 19a and 217) or
downregulated (miR-19b, 221, 222, let-7b, and let-7c) by
Activin A, an important gene that participates in the main-
tenance of pluripotency.
38
Another work reported that the miR-302 cluster on chro-
mosome 4 and the miR-520 cluster on chromosome 19
were highly expressed in undifferentiated hES cells. These
miRNAs negatively correlate with target genes with chro-
matin structure modification function and play a role in the
maintenance of chromatin structure.
39
Epithelial-mesenchymal transition
During embryogenesis, epithelial-mesenchymal transition
(EMT) plays a role in the formation of various tissues and
organs. EMT consists in the conversions of epithelial cells
to mesenchymal cells; the reverse process is called mesen-
chymal to epithelial transition (MET). Epithelial cells esta-
blish close contacts with their neighbors and an apicobasal
axis of polarity through the sequential arrangement of
adherens junctions, desmosomes, and tight junctions. The
epithelial cell layer maintains global communication thro-
ugh gap junctional complexes, and it remains separated
from adjacent tissues by a basal lamina. Epithelia have the
capacity to function as barriers or in absorption. Conver-
sely, mesenchymal or stromal cells are loosely organized
in a three-dimensional extracellular matrix and comprise
connective tissues adjacent to epithelia. The conversion of
epithelial cells to mesenchymal cells is fundamental for
embryonic development and involves profound pheno-
typic changes that include the loss of cell-cell adhesion, the
loss of cell polarity, and the acquisition of migratory and
invasive properties.
40 Most adult tissues arise from a series
of EMT and MET. However, during one’s adult life, only
a certain subset of cells retains the ability to undergo EMT.
Epithelial tumor cells often activate EMT, a latent embryo-
nic program, to acquire tumoral properties, including en-
hanced motility and an increased invasiveness capacity.
40
Recently, miRNAs have been related to the control of
EMT. Gregory, et al.
41 showed that the miR-200 family
(miR-200a, miR-200b, miR-200c, miR-141 and miR-429)
and miR-205 were key regulators of EMT. These miRNAs
were markedly downregulated in cells that had undergone
EMT in response to TGF-β ‚ and their enforced expression
was enough to prevent EMT. These miRNAs act through
their targets ZEB1 and ZEB2
41 and TGF-β 2,
42 which are E-
cadherin transcriptional repressors. These miRNAs are
thus able to enforce the epithelial phenotype through post-
transcriptional repression of these genes, allowing the
expression of E-cadherin and of polarity factors which are
integral in forming cell-cell junctions (Fig. 2). The miR-
200 family and miR-205 have been reported to be expressed
in an ephithelial-specific manner in the adult (in tissues
that contain a high proportion of epithelial cells)
43 and
during embryogenesis.
44-46 Recent findings have also con-
nected the let-7 family with the miR-200 family in EMT
and stem cell formation (reviewed in
47).
MicroRNAs in CSCs
Many cancers have small populations of CSCs, cells with
stem cell characteristics, which are a likely cause of relapse
in cancer patients. The early phases of carcinogenesis
resemble embryonic development, often involving the re-
expression of embryonic mesenchymal genes. Undifferen-
tiated stem cells display miRNA expression profiles remini-
scent of cancer cells. Numerous known oncogenic miRNAs
are expressed in early stages of development in undifferen-
tiated cells; however, their expression decreases in differen-
tiated tissue, whereas the opposite holds true for tumor
suppressive miRNAs. In a previous study, we established
what was to our knowledge the first connection between
hES cells and tumor tissues through miRNA expression.
48
We carried out a comparative study of miRNA expression
in human colon mucosa in early embryonic stages (7-8
weeks) versus late embryonic stages (9-12 weeks). Like-
wise, we compared miRNA expression in normal colon
tissue versus colorectal cancer stages I and II. Overlapping
miRNA expression was detected between embryonic colo-
nic mucosa and colorectal.
48 
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Table 1.Main microRNAs Related to Pluripotency, Self-Renewal and Differentiation in Stem Cells
Chromosome Validated Transcription  Posttranscription   
location targets regulated by regulated by
Pluripotency
Mmu-miR-290-295 7 Rbl2 c-MYC
OCT4
SOX2
NANOG
TCF3
Hsa-miR-371-372 19 TRPS1 OCT4
(human homolog of  KLF13 SOX2
miR-290-295) MBNL2 NANOG
TCF3
Hsa-miR-302-367 4 Cyclin D1 NANOG
cluster CDK4 OCT 3/4
SOX2
REX1
Hsa-let-7 family: HMGA2 c-MYC (-)
IMP-1
let-7a-1, let-7d, let-7-f-1 9 LIN28
let-7a-2 LIN28B
let-7a-3, let-7b 11 RAS
let-7c 22
let-7e 21
let-7f-2, mir-98 19
let-7g X LIN28 (let-7g)
let-7i 3
miR-202 12
10
Mmu-miR-134 12 OCT4
Mmu-miR-296 2 NANOG
Mmu-miR-470 X SOX2
Self-renewal
miR-17-92 13 E2F1 c-MYC E2F1-3
miR-15a 13 BCL2
miR-16-1 MCL1
CCND1
WNT3A
Hsa-miR-21 17 PTEN AP-1
PDC4 RECK  STAT3
MASPIN REST  (-)
NFIB TPM1
SPRY2
Hsa-miR-34 family: CDK4 P53
Hsa-miR-34a 1 CDK6
Hsa-miR-34b, c 11 Cyclin E2, D1
E2Fs
Bcl2
SIRT1
N-MYC
Notch-1/2
Differentiation
miR-200 family ZEB1 ZEB1 (-)
and miR-205 ZEB2 ZEB2 (-)
TGFB1 TGFB1To date, no specific profiles of miRNAs in CSCs have
been described. However, alterations in stem cell miRNAs
have been reported in some tumors, where they can play a
role as tumor suppressors or oncogenes.
Let-7/miR-98 family
Let-7 was the first human miRNA to be discovered. This
miRNA family is highly conserved in invertebrates and
mammals and is required for the timing of cell fate deter-
mination in C. elegans.
49,50 Many human let-7 genes map to
regions altered or deleted in human tumors,
16 indicating
that these genes function as tumor suppressors. Let-7 plays
a role in lung cancer progression, where it is downregulated
and where the postoperative survival time in lung cancer
patients directly correlated with let-7 expression levels.
51,52
Let-7 may directly control cellular proliferation by negati-
vely regulating the human RAS genes,
53 known lung cancer
oncogenes.
Moreover, let-7 is a marker for less advanced cancer and
its expression inversely correlated with HMGA2, an early
embryonic gene, but not with classical epithelial or mesen-
chymal markers, such as E-cadherin or vimentin, in SC1
and SC2 cells.
54 The expression of let-7 and HMGA2 acts
as prognostic markers in ovarian cancer.
54 The loss of let-7
in cancer occurs early during the transformation process
and results in reverse embryogenesis and dedifferentia-
tion.
55 Along these lines, we investigated whether there are
similar patterns of the let-7 family miRNA expression in
pseudoglandular human embryonic lungs and in human
lung tumors and found they were downregulated both in
embryonic lung tissue and in lung tumors. Our findings
support the model of cancer as an alteration of normal
development, as many miRNAs were similarly expressed
in early human lung development and stage I-II of lung
cancer development.
56 Moreover, let-7 has been shown to
be strikingly downregulated in mouse ES cells, where
LIN28 is highly expressed but decreases during differen-
tiation.
33 These two factors (let-7 and LIN28) form a tight
feed-back loop that is fundamental to maintaining the
precise levels of each to maintain the “stemness”, and so
their dysregulation may lead to cancer.
miR-17-92 cluster
The miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR-
20a, miR-19b-1 and miR-92-1) was one of the first re-
cognized miRNAs with an oncogenic function; the overex-
pression of the miR-17-92 cluster is known to promote cell
proliferation.
57 miR-17-92 is transcriptionally activated by
c-MYC, which in combination with Oct4, Nanog, Sox2,
and Klf4, is necessary for the generation of induced pluri-
potent stem cells.
58-63 The c-Myc-activated miR-17-92 could
thus play a role in maintaining pluripotence and self-rene-
wal in stem cells. In our study of colorectal,
48 we established
the first connection between hES cells and tumor tissue
through miRNA expression.
48 We carried out a comparative
study of miRNA expression in colon mucosa in human
embryos and colorectal cancer. We focused on the miR-
17-92 cluster and specifically on miR-17-5p, which was
overexpressed in an early embryonic colon and in stage I
and II colorectal tumors. In situ hybridization confirmed
the high level of expression of miR-17-5p in the crypt
progenitor compartment in the normal tissue (stem cell
compartment), in the epithelial embryonic tissue and in the
tumor.
48 In a similar study in lung cancer and human lung
embryogenesis, we found similar results.
56 These findings
support the potential existence of a relationship between
stem cells, cell differentiation, and cancer. Moreover, this
miRNA cluster, located in chromosome 13q31, is amplified
in a number of B-lymphomas
57 and is overexpressed in
multiple tumors, including lung, lymphoma, myeloid leuke-
mias, hepatocellular carcinomas, and colorectal.
64
Moreover, a paralog cluster of miR-17-92 - the miR-
106a-363 cluster located in chromosome X - has been
reported to have oncogenic properties. The miR-106a-363
cluster is overexpressed in 46% of human T-cell leuke-
mias, leading to increased miR-92 and miR-19 levels.
65
miR-302-367 cluster
This miRNA cluster plays an important role in the main-
tenance of pluripotency and quickly decreases after cell
differentiation and proliferation. It is also expressed in
human embryonic carcinoma cells. This miRNA cluster is
encoded in chromosome 4 and is comprised of nine
miRNAs: miR-302a, miR-302a*, miR-302b, miR-302b*,
miR-302c, miR-302c*, miR-302d, miR-367, and miR-67*
(polycistronic transcript). There is scarce evidence that this
miRNA cluster could play a role in cancer. Recently, how-
ever, Lin, et al.
66 reprogrammed human skin cancer cells
into a pluripotent ES-cell-like state with ectopic expression
of the miR-302 cluster. Moreover, some members of the
cluster are found expressed in certain acute immature
leukemia cell lines but not in normal somatic hemato-
poietic cells.
67
miR-34 family
Some miRNAs have been implicated in cell cycle control
related to p53, a crucial tumor supressor that responds to
cellular stress. Through its DNA binding domain, the p53
protein activates the expression of the miR-34 family in
response to DNA damage or oncogenic stress, leading to
apoptosis or cell cycle arrest.
68-70 The conserved miR-34
family is composed of three miRNAs: miR-34a, miR-34b,
and miR-34c. There are two miR-34 loci, one encoding
miR-34a (chromosome 1) and the other encoding both
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regions of both loci contain a p53-binding site.
68 The miR-
34 family has been shown to form part of the p53 net-
work,
68,71 and its expression is directly induced by p53 in
response to DNA damage or oncogenic stress. Moreover,
the promoter region of the MIRN34A gene contains CpG
islands, and aberrant CpG methylation that reduces miR-
34a expression levels has been reported in multiple types
of cancer.
72 The high frequency of miR-34 silencing in
tumors suggests that the miR-34 family acts as a tumor
suppressor gene, indicating a potential role as a prognostic
marker. Recently, our group identified miR-34a as a pro-
gnostic marker of relapse in NSCLC patients; patients with
both p53 mutations and low miR-34a levels had the highest
probability of relapse.
69 Moreover, miR-34a has been shown
to play a role in chemotherapy resistance in CLL.
73
The miR-34 family has been related to the Notch path-
way, an important pathway during normal development
where it acts to regulate many cellular processes. miR-34a
targets several mRNAs, such as SIRT1, Bcl-2, N-myc, and
Cyclin D1, and has recently been reported to target Notch-1,
Notch-2, and CDK6. In pancreatic cancer, stem cells have
high levels of Notch-1/2 and loss of miR-34, suggesting
that miR-34 is involved in the regulation of pancreatic
CSCs via regulation of the Notch pathway.
74
miR-15, miR-16
miR-15 and miR-16 were two of the first indentified
miRNAs with a tumor suppressor function. These miRNAs
are encoded in 13q14, a region often implicated in cancer,
and they are frequently deleted and/or downregulated in
chronic lymphocytic leukemia (CLL).
75 Expression of these
miRNAs inhibits cell proliferation, promotes apoptosis,
and suppresses tumorigenicity both in vitro and in vivo
(reviewed in
76) by targeting multiple oncogenes, including
BCL2, MCL1, CCND1, and WNT3A. Downregulation of
these miRNAs has been reported in CLL,
75 pituitary adeno-
mas,
77 prostate carcinoma,
78 NSCLC,
79 and ovarian cancer.
80
These miRNAs play a key role in CSC regulation and in
tumor cells, where they help to control self-renewal through
cell cycle control.
81 Moreover, in ovarian cancer, these
miRNAs regulate Bmi-1. Bmi-1 plays a key role in regulat-
ing the proliferative activity of normal stem and progenitor
cells.
82 It is also indispensable for the self-renewal of neural
83
and hematopoietic stem cells.
84 Oncogenic activation of
Bmi-1 is found in a wide variety of epithelial malignan-
cies, including ovarian cancer, where it correlates with the
downregulation of miR-15/16.
81
Recently, miR-16 has been linked to the p53 pathway.
Suzuki, et al.
85 have shown that p53 interacts with proteins
of the Drosha complex to promote processing of a subset
of miRNAs, including miR-16-1. We have analyzed the
prognostic implications of miR-16 levels in NSCLC pati-
ents and found that miR-16 works as a marker for disease-
free and overall survival marker in these patients (unpub-
lished data).
miR-21
miR-21 is encoded in chromosome 17q23 and is overex-
pressed in a large number of tumors, including breast
cancer, Hodgkin lymphoma,
86 leukemia, glioma, head and
neck cholangiocarcinoma,
87 hepatocellular carcinoma,
88
colorectal,
48,89 cervical, ovarian, and pancreatic cancer.
64  In
these tumors, miR-21 promotes proliferation by inhibiting
apoptosis and promotes invasion by acting on different
targets: PDC4, PTEN, RECK, MASPIN, NFIB, TPM1, or
SPRY2 (reviewed in
90). In contrast, relatively low expres-
sion of miR-21 was observed in the HL-60 (promyelocytic
leukemia) and the K562 (chronic myelogenous leukemia)
cell lines and in a prostatic adenocarcinoma cell line. The
transcription of miR-21 has been shown to be activated by
AP-1
91 and STAT3,
92 and the overexpression of miR-21 in
multiple types of cancers may reflect an elevated AP-1or
STAT3 activity. In contrast to its high expression in tumors,
miR-21 expression was low in ES cells, where miRNAs
play a complex role in self-renewal/proliferation, since
REST, a gene essential for pluripotency and self-renewal,
binds to the miR-21 promoter region, and represses its
expression.
93
miR-200 family and miR-205
Recent evidence suggests that cells that undergo EMT
acquire stem cell-like properties.
94,95 Moreover, it has been
showed that ES cells can adopt a mesenchymal phenotype
without losing their pluripotency.
96,97 Loss of the miR-200
family seems to be a late-stage event in epithelial tumor
progression, occurring in de-differentiated tumor cells with
a greater metastatic capacity via EMT (Fig. 3).The miR-
200 family and miR-205 have been reported to be dysre-
gulated in specific cancers. The miR-200 family is down-
regulated in benign liver tumors
98 and upregulated in ovar-
ian
99 and cholangyocyte
100 tumors. Our group has observed
overexpression of the miR-200 family in colorectal cancer
(non-published data). miR-205 is downregulated in breast
cancer
101 and esophageal tumors
87 and upregulated in ovar-
ian
99 and bladder tumors.
102 The miR-200 family and miR-
205 are also downregulated in poorly differentiated tumors
and mesenchymal cancer cell lines. 
Microvesicles
Microvesicles (MVs) are plasma membrane-derived vesi-
cles (from -30 nm to 1 µm), originally considered inert cel-
lular debris, released into the extracellular environment by
a variety of cell types, including ES cells and tumor cells.
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103 MVs are a nor-
mal constituent of human plasma, where they play an im-
portant role in maintaining hematostasis. MVs contain a
variety of elements, including proteins, lipids, and RNA,
and recently it has been shown that they are enriched in
miRNAs.
104 MVs play a role in stem cell-microenviron-
ment communication, where MVs account for the transfer
of genetic information between the microenvironment and
stem cells, thus modulating the stem-phenotype.
105  Recen-
tly, MVs have been isolated from ES cells. These ES cell
microvesicles (ESMVs) were capable of reprogramming
hematopoietic progenitors.
106 Moreover, ES cells produce
microvesicles which contain abundant miRNAs.
107 Tumor
cells can also release MVs, which can be detected in the
plasma of cancer patients,
108 where they may function as
prognostic markers. In ovarian cancer, eight miRNAs
(miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-
203, miR-205, and miR-214) previously shown to be
diagnostic were found more highly expressed in MVs from
advanced ovarian cancer patients than in patients with
benign ovarian diseases; moreover, these miRNAs were
not present in normal controls.
109 These miRNAs could be
useful as diagnostic biomarkers in tumors like NSCLC.
109
The detection of miRNAs in plasma/serum MVs in cancer
patients opens a new window for tumor screening and
therapeutic approaches.
miRNAs have emerged as key regulators of “stemness”,
collaborating in the maintenance of pluripotency, control
of self-renewal, and differentiation of stem cells. Recently,
several breakthroughs have increased our knowledge of
the role of miRNAs in stem cells. Firstly, miRNAs expre-
ssed specifically in ES cells have been identified. Secon-
dly, recent findings indicate that cancer may arise from
stem cells (CSCs) and that many cell signaling pathways
essential for normal development are also involved in
cancer initiation and progression. Moreover, overlapping
expression patterns of miRNAs have been identified in
embryonic and cancer cells. Taken together, these findings
provide hints that a strong link exists between embryonic
cells and cancer cells. Thirdly, miRNAs have been linked
to the main pathways of stem cells, where some miRNAs
regulate or are regulated by stem cell-genes such as Nanog,
Oct4, or Sox2. Finally, although miRNAs are not at the top
of the stem cell hierarchy, they are crucial intermediate
regulators, and the ectopic expression of certain miRNAs,
such as the miR-302-367 cluster, can induce pluripotency.
As we increase our knowledge of miRNAs in ES cells, we
will be able to identify new targets in the fight against
tumors. CSCs are responsible for relapse and treatment
failure in many cancer patients, and the comparative analy-
sis of expression patterns between ES cells and tumors can
lead to the identification of a miRNA signature to define
CSCs. Most of the key miRNAs identified to date in ES
cells have been shown to play a role in tumor diagnosis or
prognosis and may well prove to be essential in cancer
therapy in the foreseeable future. 
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